ReviewNature reviews. Gastroenterology & hepatology2015
Crosstalk at the mucosal border: importance of the gut microenvironment in IBS.
Review in Nature reviews. Gastroenterology & hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 4 syntheses or guidelines pooled it, 173 citations in OpenAlex.
- Alterations in short-chain fatty acids and serotonin in irritable bowel syndrome: a systematic review and meta-analysis.BMC gastroenterology · 2021Pooled it
- Parental, Perinatal, and Childhood Risk Factors for Development of Irritable Bowel Syndrome: A Systematic Review.Journal of neurogastroenterology and motility · 2020Pooled it
- Alterations of Gut Microbiota in Patients With Irritable Bowel Syndrome Based on 16S rRNA-Targeted Sequencing: A Systematic Review.Clinical and translational gastroenterology · 2019Pooled it
- Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis.BMC gastroenterology · 2016Pooled it
- Fecal microbiota transplantation influences microbiota without connection to symptom relief in irritable bowel syndrome patients.NPJ biofilms and microbiomes · 2024Trial
- Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial.European journal of nutrition · 2024Trial
- Impact of bread diet on intestinal dysbiosis and irritable bowel syndrome symptoms in quiescent ulcerative colitis: A pilot study.PloS one · 2024Trial
- Randomised controlled trial: effects of gluten-free diet on symptoms and the gut microenvironment in irritable bowel syndrome.Alimentary pharmacology & therapeutics · 2022Trial
- Fecal microbiota transplantation in the treatment of irritable bowel syndrome: a single-center prospective study in Japan.BMC gastroenterology · 2022Trial
- Predictors of Symptom-Specific Treatment Response to Dietary Interventions in Irritable Bowel Syndrome.Nutrients · 2022Trial
- Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome.World journal of gastroenterology · 2021Trial
- Changes in serum and urinary metabolomic profile after a dietary intervention in patients with irritable bowel syndrome.PloS one · 2021Trial
- Trial
- Clinical hallmarks and peripheral immune factors associated with antipsychotic-induced constipation in schizophrenia.Therapeutic advances in psychopharmacology · 2026Article
- Remission of Alopecia Areata Post-colectomy in a Patient with Crohn's Disease.The Journal of clinical and aesthetic dermatology · 2025Article
- Dietary microbes and functional dyspepsia: modulating the gut microecology for therapeutic benefit.Frontiers in nutrition · 2025Review
- Quantitative sensory testing and chronic pain syndromes: a cross-sectional study from TwinsUK.BMJ open · 2024Article
- Current and Future Therapeutic Options for Irritable Bowel Syndrome with Diarrhea and Functional Diarrhea.Digestive diseases and sciences · 2023Review
- Constipation-Predominant Irritable Bowel Syndrome (IBS-C): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms.Nutrients · 2023Review
- Associations between postprandial symptoms, hydrogen and methane production, and transit time in irritable bowel syndrome.Neurogastroenterology and motility · 2023Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aetiology and pathology of IBS, a functional bowel disorder thought to lack an organic cause, is largely unknown. However, studies suggest that various features, such as altered composition of the gut microbiota, together with increased intestinal permeability, a changed balance in the enteroendocrine system and a dysregulated immune system in the gut, most likely have an important role in IBS. Exactly how these entities act together and give rise to symptoms is still unknown, but an altered gut microbiota composition could lead to dysregulation of the intestinal barrier as well as the enteroendocrine and the immune systems, which (through interactions with the nervous system) might generate symptoms. This Review highlights the crosstalk between the gut microbiota, the enteroendocrine system, the immune system and the role of intestinal permeability in patients with IBS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.